216 related articles for article (PubMed ID: 26822232)
1. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.
Eslam M; Mangia A; Berg T; Chan HL; Irving WL; Dore GJ; Abate ML; Bugianesi E; Adams LA; Najim MA; Miele L; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Romero-Gomez M; Spengler U; Nattermann J; Rahme A; Sheridan D; Booth DR; McLeod D; Powell E; Liddle C; Douglas MW; van der Poorten D; George J;
Hepatology; 2016 Jul; 64(1):34-46. PubMed ID: 26822232
[TBL] [Abstract][Full Text] [Related]
2. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.
Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ
Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781
[TBL] [Abstract][Full Text] [Related]
3. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.
Borén J; Adiels M; Björnson E; Matikainen N; Söderlund S; Rämö J; Ståhlman M; Ripatti P; Ripatti S; Palotie A; Mancina RM; Hakkarainen A; Romeo S; Packard CJ; Taskinen MR
JCI Insight; 2020 Dec; 5(24):. PubMed ID: 33170809
[TBL] [Abstract][Full Text] [Related]
4. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.
Petta S; Maida M; Grimaudo S; Pipitone RM; Macaluso FS; Cabibi D; Cammà C; Di Marco V; Sferrazza S; Craxì A
Liver Int; 2016 Feb; 36(2):198-204. PubMed ID: 26259026
[TBL] [Abstract][Full Text] [Related]
5. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.
Xu M; Li Y; Zhang S; Wang X; Shen J; Zhang S
Ann Hepatol; 2019; 18(3):456-460. PubMed ID: 31054977
[TBL] [Abstract][Full Text] [Related]
6. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism.
Coppola N; Rosa Z; Cirillo G; Stanzione M; Macera M; Boemio A; Grandone A; Pisaturo M; Marrone A; Adinolfi LE; Sagnelli E; Miraglia del Giudice E
Liver Int; 2015 Aug; 35(8):1959-63. PubMed ID: 25581573
[TBL] [Abstract][Full Text] [Related]
7. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
[TBL] [Abstract][Full Text] [Related]
8. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
[TBL] [Abstract][Full Text] [Related]
9. The Genetics of Clinical Liver Diseases: Insight into the
Zhang X; Liu S; Dong Q; Xin Y; Xuan S
J Clin Transl Hepatol; 2018 Sep; 6(3):326-331. PubMed ID: 30271746
[TBL] [Abstract][Full Text] [Related]
10. Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease.
Xue WY; Zhang L; Liu CM; Gao Y; Li SJ; Huai ZY; Dai J; Wang YY
Expert Rev Gastroenterol Hepatol; 2022 Feb; 16(2):97-107. PubMed ID: 35057689
[TBL] [Abstract][Full Text] [Related]
11. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients.
Milano M; Aghemo A; Mancina RM; Fischer J; Dongiovanni P; De Nicola S; Fracanzani AL; D'Ambrosio R; Maggioni M; De Francesco R; Fargion S; Berg T; Stickel F; Hampe J; Romeo S; Colombo M; Valenti L
Hepatology; 2015 Jul; 62(1):111-7. PubMed ID: 25820484
[TBL] [Abstract][Full Text] [Related]
12. The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis.
Liu Z; Que S; Zhou L; Zheng S; Romeo S; Mardinoglu A; Valenti L
Sci Rep; 2017 Aug; 7(1):9273. PubMed ID: 28839198
[TBL] [Abstract][Full Text] [Related]
13. TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.
Sagnelli C; Merli M; Uberti-Foppa C; Hasson H; Grandone A; Cirillo G; Salpietro S; Minichini C; Starace M; Messina E; Morelli P; Miraglia Del Giudice E; Lazzarin A; Coppola N; Sagnelli E
World J Gastroenterol; 2016 Oct; 22(38):8509-8518. PubMed ID: 27784963
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
[TBL] [Abstract][Full Text] [Related]
15. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.
Liu YL; Reeves HL; Burt AD; Tiniakos D; McPherson S; Leathart JB; Allison ME; Alexander GJ; Piguet AC; Anty R; Donaldson P; Aithal GP; Francque S; Van Gaal L; Clement K; Ratziu V; Dufour JF; Day CP; Daly AK; Anstee QM
Nat Commun; 2014 Jun; 5():4309. PubMed ID: 24978903
[TBL] [Abstract][Full Text] [Related]
16. TM6SF2 rs58542926 is related to hepatic steatosis, fibrosis and serum lipids both in adults and children: A meta-analysis.
Li XY; Liu Z; Li L; Wang HJ; Wang H
Front Endocrinol (Lausanne); 2022; 13():1026901. PubMed ID: 36353245
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of the influence of TM6SF2 E167K variant on Plasma Concentration of Aminotransferases across different Populations and Diverse Liver Phenotypes.
Sookoian S; Pirola CJ
Sci Rep; 2016 Jun; 6():27718. PubMed ID: 27278285
[TBL] [Abstract][Full Text] [Related]
18. TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease.
Luo F; Oldoni F; Das A
Hepatol Commun; 2022 Mar; 6(3):448-460. PubMed ID: 34532996
[TBL] [Abstract][Full Text] [Related]
19. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.
Luukkonen PK; Zhou Y; Nidhina Haridas PA; Dwivedi OP; Hyötyläinen T; Ali A; Juuti A; Leivonen M; Tukiainen T; Ahonen L; Scott E; Palmer JM; Arola J; Orho-Melander M; Vikman P; Anstee QM; Olkkonen VM; Orešič M; Groop L; Yki-Järvinen H
J Hepatol; 2017 Jul; 67(1):128-136. PubMed ID: 28235613
[TBL] [Abstract][Full Text] [Related]
20. Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population.
Li Y; Liu S; Gao Y; Ma H; Zhan S; Yang Y; Xin Y; Xuan S
BMC Biochem; 2019 Feb; 20(1):3. PubMed ID: 30727943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
